Amin AL - Search Results

1

Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual Disease.

Cao L, Shenk R, Stabellini N, Amin AL, Montero AJ, Towe CW. Cao L, et al. Among authors: amin al. J Surg Res. 2023 May;285:114-120. doi: 10.1016/j.jss.2022.12.011. Epub 2023 Jan 17. J Surg Res. 2023. PMID: 36657304

2

A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.

Cao L, Towe CW, Shenk R, Stabellini N, Amin AL, Montero AJ. Cao L, et al. Among authors: amin al. Cancer. 2022 Jul 1;128(13):2433-2440. doi: 10.1002/cncr.34200. Epub 2022 Apr 1. Cancer. 2022. PMID: 35363881 Free article.

3

Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer".

Cao L, Stabellini N, Amin AL, Montero AJ. Cao L, et al. Among authors: amin al. Cancer. 2022 Aug 15;128(16):3130. doi: 10.1002/cncr.34339. Epub 2022 Jun 7. Cancer. 2022. PMID: 35670117 Free article. No abstract available.

4

[No title available]

[No authors listed] [No authors listed] PMID: 35925532

5

Rethinking Routine Surgical Excision for all Radial Sclerosing Lesions of the Breast.

Patel M, Aripoli A, Chollet-Hinton L, Larson KE, Balanoff CR, Kilgore LJ, Amin AL. Patel M, et al. Among authors: amin al. J Surg Res. 2022 Nov;279:611-618. doi: 10.1016/j.jss.2022.06.048. Epub 2022 Aug 1. J Surg Res. 2022. PMID: 35926311

6

Age disparities in triple-negative breast cancer treatment and outcomes: An NCDB analysis.

Drapalik LM, Estes A, Sarode AL, Cao L, Shenk RR, Jarrett CM, Amin AL, Miller ME. Drapalik LM, et al. Among authors: amin al. Surgery. 2022 Sep;172(3):821-830. doi: 10.1016/j.surg.2022.05.026. Epub 2022 Aug 1. Surgery. 2022. PMID: 35927082

7

Guideline-Consistent Treatment for Inflammatory Breast Cancer Provides Associated Survival Benefit Independent of Age.

Drapalik LM, Hue JJ, Simpson A, Freyvogel M, Rock L, Shenk RR, Amin AL, Miller ME. Drapalik LM, et al. Among authors: amin al. Ann Surg Oncol. 2022 Oct;29(10):6469-6479. doi: 10.1245/s10434-022-12237-1. Epub 2022 Aug 8. Ann Surg Oncol. 2022. PMID: 35939169

8

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis.

Stabellini N, Cao L, Towe CW, Luo X, Amin AL, Montero AJ. Stabellini N, et al. Among authors: amin al. Front Oncol. 2023 Apr 24;13:1115208. doi: 10.3389/fonc.2023.1115208. eCollection 2023. Front Oncol. 2023. PMID: 37168373 Free PMC article.

9

Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.

Stabellini N, Cao L, Towe CW, Amin AL, Montero AJ. Stabellini N, et al. Among authors: amin al. Cancer Med. 2023 Oct;12(19):19607-19616. doi: 10.1002/cam4.6584. Epub 2023 Sep 28. Cancer Med. 2023. PMID: 37766666 Free PMC article.

10

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.

Stabellini N, Cao L, Towe CW, Miller ME, Sousa-Santos AH, Amin AL, Montero AJ. Stabellini N, et al. Among authors: amin al. J Natl Compr Canc Netw. 2023 Oct;21(10):1011-1019.e6. doi: 10.6004/jnccn.2023.7048. J Natl Compr Canc Netw. 2023. PMID: 37856198

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters